Trial Profile
A Multi-center, Intra-patient Dose Escalation Phase II Study to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Dumping syndrome
- Focus Therapeutic Use
- Sponsors Novartis
- 25 Apr 2018 Primary endpoint (Response Rate in Plasma Glucose Level) has been met, according to results published in the Alimentary Pharmacology and Therapeutics.
- 25 Apr 2018 Results (n=43) assessing the efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome, were published in the Alimentary Pharmacology and Therapeutics.
- 11 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.